Institution
Wuhan University
Education•Wuhan, China•
About: Wuhan University is a education organization based out in Wuhan, China. It is known for research contribution in the topics: Computer science & Population. The organization has 92849 authors who have published 92882 publications receiving 1691049 citations. The organization is also known as: WHU & Wuhan College.
Topics: Computer science, Population, Catalysis, Feature extraction, Apoptosis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness and may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.
Abstract: Background The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. Methods The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. Results The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. Conclusions The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.
503 citations
••
TL;DR: Surface-bound, rather than free radicals generated by a surface catalyzed-redox cycle involving both Fe(III) and Cu(II), are postulated to be responsible for the mineralization of bisphenol A.
503 citations
••
TL;DR: The high-risk department, longer duty hours, and suboptimal hand hygiene after contacting with patients after contact with patients were linked to COVID-19.
Abstract: Coronavirus Disease 2019 (COVID-19), which originated in Wuhan, China, has caused many healthcare workers (HCWs) to be infected. Seventy-two HCWs manifested with acute respiratory illness were retrospectively enrolled to analyze the risk factors. The high-risk department, longer duty hours, and suboptimal hand hygiene after contacting with patients were linked to COVID-19.
502 citations
••
University of Sharjah1, McMaster University2, Kuwait Cancer Control Center3, University of Toronto4, University of Texas MD Anderson Cancer Center5, Min Sheng General Hospital6, National University of Singapore7, University of Western Ontario8, Vanderbilt University9, University of Tennessee Health Science Center10, Wuhan University11
TL;DR: The potential challenges associated with managing cancer patients during the COVID‐19 infection pandemic will be addressed, with suggestions of some practical approaches.
Abstract: The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). In December 2019, an outbreak of atypical pneumonia, known as COVID-19, was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by rapid human-to-human transmission. Many cancer patients frequently visit the hospital for treatment and disease surveillance. They may be immunocompromised due to the underlying malignancy or anticancer therapy and are at higher risk of developing infections. Several factors increase the risk of infection, and cancer patients commonly have multiple risk factors. Cancer patients appear to have an estimated twofold increased risk of contracting SARS-CoV-2 than the general population. With the WHO declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such a pandemic on cancer patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the management of cancer patients in any infectious pandemic. In this review, the potential challenges associated with managing cancer patients during the COVID-19 infection pandemic will be addressed, with suggestions of some practical approaches. IMPLICATIONS FOR PRACTICE: The main management strategies for treating cancer patients during the COVID-19 epidemic include clear communication and education about hand hygiene, infection control measures, high-risk exposure, and the signs and symptoms of COVID-19. Consideration of risk and benefit for active intervention in the cancer population must be individualized. Postponing elective surgery or adjuvant chemotherapy for cancer patients with low risk of progression should be considered on a case-by-case basis. Minimizing outpatient visits can help to mitigate exposure and possible further transmission. Telemedicine may be used to support patients to minimize number of visits and risk of exposure. More research is needed to better understand SARS-CoV-2 virology and epidemiology.
499 citations
••
TL;DR: A conceptually different approach toward the biaryl syntheses is uncovered by using DMEDA as the catalyst to promote the direct C-H arylation of unactivated benzene in the presence of potassium tert-butoxide.
Abstract: A striking breakthrough to the frame of traditional cross-couplings/C-H functionalizations using an organocatalyst remains unprecedented. We uncovered a conceptually different approach toward the biaryl syntheses by using DMEDA as the catalyst to promote the direct C-H arylation of unactivated benzene in the presence of potassium tert-butoxide. The arylation of unactivated benzene with aryl iodides, or aryl bromides and even chlorides under the assistance of an iodo-group, could simply take place at 80 °C. The new methodology presumably involves an aryl radical anion as an intermediate. This finding offers an option toward establishing a new horizon for direct C-H/cross-coupling reactions.
499 citations
Authors
Showing all 93441 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jing Wang | 184 | 4046 | 202769 |
Jiaguo Yu | 178 | 730 | 113300 |
Lei Jiang | 170 | 2244 | 135205 |
Gang Chen | 167 | 3372 | 149819 |
Omar M. Yaghi | 165 | 459 | 163918 |
Xiang Zhang | 154 | 1733 | 117576 |
Yi Yang | 143 | 2456 | 92268 |
Thomas P. Russell | 141 | 1012 | 80055 |
Jun Chen | 136 | 1856 | 77368 |
Lei Zhang | 135 | 2240 | 99365 |
Chuan He | 130 | 584 | 66438 |
Han Zhang | 130 | 970 | 58863 |
Lei Zhang | 130 | 2312 | 86950 |
Zhen Li | 127 | 1712 | 71351 |
Chao Zhang | 127 | 3119 | 84711 |